Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen Anticipates Continued Growth in Sales of Ikervis in Europe; 30% Overseas Sales Ratio an “Achievable Target”
May 17, 2016
- As Tagrisso Launch Nears, AZ Pushes Stringent Prerequisites for Facilities, Doctors to Ensure Safety
May 17, 2016
- Towa to Mull Over Distribution Dealing with Wholesalers
May 17, 2016
- Eisai Aims for 10% Rise in Japan Pharma Sales with Patented Products: CEO
May 16, 2016
- Eisai Posts Higher Profits despite Sales Dip, Global Brands Expand
May 16, 2016
- Kyorin Enthusiastic about Overcoming “Kipres Cliff,” Aiming for Over 50% Share with AG, 4 New Product Launches
May 16, 2016
- Ono to Erect New Opdivo Plant, Operational Launch Eyed for 2020
May 13, 2016
- US Merck Links Up with Univ. of Tokyo on Drug Discovery
May 13, 2016
- Takeda Taps Ex-Kraft Foods CFO Kehoe as New CFO
May 13, 2016
- Daiichi Sankyo CEO Sees High Odds of Success for AML Drug Quizartinib
May 13, 2016
- Daiichi Sankyo Sees 7.3% Sales Rise, but Girding for FY2016 Dip on Olmesartan Cliff
May 13, 2016
- Kissei Ditches Constipation Drug KWA-0711, Turns to Other Products for GI Entry
May 13, 2016
- Nichi-Iko to Develop 3 Biosimilars for Global Market, Aims to Enter as Global Top-10 Generic Maker within 3 Years
May 13, 2016
- Santen’s FY2015 Profits Zoom on Sale of RA Business
May 13, 2016
- Astellas Unveils List of Approval Hopefuls in FY2016
May 12, 2016
- Astellas Looking at Japan Filing of Romosozumab by March 2017
May 12, 2016
- Under New Name, Ocata Positioned as R&D Hub for Regenerative Medicine, Ophthalmology: Astellas
May 12, 2016
- Sumitomo Dainippon’s Sales Cross 400 Billion Yen as Latuda Becomes Blockbuster in N. America
May 12, 2016
- Shionogi Scores Record Operating Profit as Royalties Spike
May 12, 2016
- Mitsubishi Tanabe’s Sales Rise on Royalty, Upfront Revenues
May 12, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…